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Background: Notch signalling regulates cell fate in most tissues, promoting precursor cell proliferation in some, but
differentiation in others. Accordingly, downregulation or overactivity variously contributes to cancer development.
So far, little is known about Notch pathway activity and function in the normal urothelium and in urothelial
carcinoma (UC). We have therefore investigated expression of Notch pathway components in UC tissues and cell
lines and studied the function of one receptor, NOTCH1, in detail.
Methods: Expression of canonical Notch pathway components were studied in UC and normal bladder tissues by
immunohistochemistry and quantitative RT-PCR and in UC cell lines and normal cultured urothelial cells by
qRT-PCR, immunocytochemistry and Western blotting. Pathway activity was measured by reporter gene assays.
Its influence on cell proliferation was investigated by γ-secretase inhibition. Effects of NOTCH1 restoration were
followed by measuring cell cycle distribution, proliferation, clonogenicity and nuclear morphology.
Results: NOTCH1 and its ligand, DLL1, were expressed at plasma membranes and in the cytoplasm of cells in the
upper normal urothelium layer, but became downregulated in UC tissues, especially in high-stage tumours. In
addition, the proteins were often delocalized intracellularly. According differences were observed in UC cell lines
compared to normal urothelial cells. Canonical Notch pathway activity in reporter assays was repressed in UC cell
lines compared to normal cells and a mammary carcinoma cell line, but was induced by transfected NOTCH1.
Inhibitors of Notch signalling acting at the γ-secretase step did not affect UC cell proliferation at concentrations
efficacious against a cell line with known Notch activity. Surprisingly, overexpression of NOTCH1 into UC cell lines
did not significantly affect short-term cell proliferation, but induced nuclear abnormalities and diminished
clonogenicity.
Conclusion: Our data indicate that canonical Notch signalling is suppressed in urothelial carcinoma mainly through
downregulation of NOTCH1. These findings can be explained by proposing that canonical Notch signalling may
promote differentiation in the urothelium, like in many squamous epithelia, and its suppression may therefore be
advantageous for tumour progression. As an important corollary, inhibition of canonical Notch signalling is unlikely
to be efficacious and might be counter-productive in the treatment of urothelial carcinoma.
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Bladder cancer is the fifth most common malignancy in
most Western industrialized countries with urothelial
carcinoma (UC) representing the major histological sub-
type. UC can be further classified into papillary and in-
vasive carcinomas [1]. While most cases of papillary low
grade urothelial tumours have a good prognosis, high
grade papillary tumours tend to progress towards inva-
sive cancers which are often lethal. A large fraction of
invasive urothelial carcinomas develop by a different
route via high-grade dysplastic carcinoma in situ [2].
Depending on tumour stage, urothelial carcinoma treat-
ment is treated either by transurethral resection or ra-
dical cystectomy. In addition neo-adjuvant or palliative
chemotherapy is used in locally advanced or metastatic
urothelial carcinomas, respectively [3,4]. Local immuno-
therapy or chemotherapy is used for preventing recur-
rences of superficial cancers. Until now, clinical studies
using molecular targeted drugs have yielded disappoin-
ting results [5-7]. This failure is generally considered to
reflect our insufficient knowledge of urothelial tumour
biology.
The Notch signalling pathway is a promising target for
cancer therapy [8,9]. In many tissues, Notch signalling
contributes to the maintenance of stem cells or precursor
cells [10] and pathway hyperactivation caused by point
mutations [11] or translocations involving NOTCH genes
[12,13] is oncogenic by blocking cell differentiation, pro-
tecting against apoptosis and stimulating proliferation.
Conversely, in certain epithelia, Notch signalling promotes
differentiation. Accordingly, pathway inactivation, fre-
quently caused by NOTCH1 mutations, is observed in
squamous carcinomas of several organs [14-16]. Therefore,
depending on tissue and tumour type, drugs targeting
Notch signalling may be therapeutic, useless or tumour-
promoting [17].
Notch signalling constitutes a short-range commu-
nication system between adjacent cells. Canonical Notch
signalling is activated by ligand-receptor interactions
releasing the receptor intracellular domain (NICD) by
two proteolytic steps, including an essential cleavage by
γ-secretase. The NICD translocates into the nucleus
where it binds to C Promoter Binding Factor-1 (CBF-1),
recruits co-activators (MAML1 and KDM5A) and typi-
cally activates the transcription of Hairy and Enhancer of
Split (HES) and Hairy and Enhancer of Split related (HEY)
target genes. Through such effectors Notch determines
cell fate [18].
To date, little information exists on the Notch signal-
ling pathway in normal urothelium or urothelial cancers.
Decreased expression of several Notch receptors and
ligands in immunohistochemistry has been reported es-
pecially in papillary UC [19]. We have investigated the
expression of Notch pathway components in urothelialcarcinoma tissues and cell lines and the function of
NOTCH1 in UC cell lines.
Methods
Tissue samples
The benign and tumour bladder samples used for gene
expression studies were a subset of those described pre-
viously [20] comprising 11 benign bladder tissues and 30
bladder cancer tissues from 25 male and 5 female pa-
tients with ages ranging from 54 to 84 years. Tumour
stages and grading according to the UICC classification
were as follows: pT3 G3 in 11 cases, pT4 G3 in 6 cases,
pT2 G2 in 6 cases, pT2 G3 in 3 cases and one case each
of pT3 G2, pT1 G2, pTa G3 and pTa G2 tumours. The
set used for immunohistochemistry comprised 4 normal
tissues, 27 UC tissues with 6 pTa low grade, 5 pTa high
grade, 5 pT1, 3 pT2, 3 pT3, 4 pT4, 1 CIS. The study was
approved by the ethics committee of the medical faculty
of the Heinrich Heine University and informed consent
was obtained from all patients.
Cell lines and primary cultures
All UC cell lines (5637, 639v, 647v, BFTC905, HT1376,
J82, RT4, RT112, SD, SW1710, UM-UC3, VM-Cub1, T24)
and HEK293 cells were cultured in DMEM GlutaMax
(Gibco, Darmstadt, Germany), supplemented with 10%
fetal calf serum [21]. They were obtained from the DSMZ
(Braunschweig, Germany), except for UM-UC3, kindly
provided by Dr. Grossman, Houston. The well-differen-
tiated UC cell line BC61 was cultured and characterized
as previously described [22,23]. Primary urothelial cells
(UP) were prepared and maintained as described (20).
T47D cells were maintained in RPMI1640 supplemented
with 15% foetal calf serum and 10 μg/ml insulin.
Plasmids
Human N1ICD-pIRES2 was a kind gift from Prof.
Giebel, Essen; human full-length wildtype NOTCH1 in
a pcDNA3-HA/FLAG vector was kindly provided by
Prof. Di Fiore, IFOM, Italy [24].
Gamma secretase inhibitor treatment
Cells were treated with 0.25 - 20 μM γ-secretase inhibi-
tors DAPT (#2634, TOCRIS/R&D Systems), L-685,458
(#2627, TOCRIS/R&D Systems) or Compound E (#56597,
Calbiochem/Millipore) or, as a control, compound W
(#2654, TOCRIS/R&D Systems) for 48 h when viability
was analysed by MTTassay.
Transfection and reporter gene assay
For reporter gene assays, cells seeded in 6-well plates
were transiently transfected with XtremeGene9 (Roche)
with 1 μg of either pJH26A (Notch responsive reporter)
or pJH28A (Notch non-responsive reporter), kindly
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ments either pHES1 (+CBF1)-luc (addgene 41723; simi-
lar to pJH26A) or pHES1 lacking the CBF1 site (addgene
43805, similar to pJH28A). p850-luc and pGL3 (Pro-
mega) were used as positive or negative controls, re-
spectively. NOTCH1 expression plasmids were added as
indicated in the individual experiments, using the re-
spective plasmid vectors for adjusting total amounts
transfected. All cells were co-transfected with 10 ng
Renilla luciferase plasmid for normalization. Cells were
harvested 48 h after transfection and assayed for lucifer-
ase activities by the Dual-Luciferase reporter assay (Pro-
mega). Notch activity was determined as the ratio of
wildtype to mutant plasmids and normalized to p850-luc
and Renilla luciferase activity.Ligand dependent Notch activation assay
The ligand-dependent activation assay was carried out
as described [26]. Briefly, urothelial cancer cell lines
seeded in 6 well plates were co-transfected at 80% con-
fluency with NOTCH1 full-length expression plasmid
(or vector), the Notch-responsive reporters pJH26A or
pJH28A and Renilla luciferase plasmid at a 1:1:0.1 ratio.
After 24 h cells were replated in triplicates in 24 well
plates coated with ligand or controls. For that purpose,
the wells were first coated with 20 μg/ml goat anti-human
IgG1C Fc secondary antibody (ThermoFisher Scientific,
Germany), washed, and then incubated for 2 h with
10 μg/ml DLL1 extracellular domain (aa 1–545) fused at
its C-terminus to the Fc portion of human IgG (DLL1:Fc;
AdipoGen, Switzerland) or human IgG (ThermoFisher
Scientific, Germany), followed by a further wash. After a
further 24 h, cells were harvested and assayed for luci-
ferase activities by the Dual-Luciferase reporter assay
(Promega). Basal activity in cells exposed to immobilized
IgG was set as 1 for each cell line.Colony forming assay
For the colony forming assay 105 cells were seeded in 6
well plates and transfected with pIRES2-N1ICD or the
corresponding pIRES2 empty vector, or with pcDNA4/
to-Notch1 full-length (N1-FL) or the corresponding
pcDNA4/to-lacZ plasmid. After 24 h cells were seeded in
triplicates into 10 cm plates and selection for stable inte-
gration of the plasmids was started the next day. Cells
transfected with pIRES2 plasmids were treated with 1.0 -
1.8 mg/ml Geneticin Selective Antibiotic G418-Sulfat
(Invitrogen) and cells transfected with pcDNA4/to-plasmids
were treated with 100–150 μg/ml Zeocin Selection Reagent
(Invitrogen) every two days for 2 weeks. After a one week
recovery period with lower antibiotic concentrations, the
remaining colonies were fixed with 100% methanol and
stained with Giemsa solution (Sigma-Aldrich, Germany).Colonies were then counted and statistical comparisions
were made by Student’s T-Test.RNA isolation and RT-PCR
Total RNA was isolated from sub-confluent cell lines using
the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA
was reverse transcribed using 200 U SuperScriptII re-
verse transcriptase (Invitrogen, Darmstadt, Germany), with
300 ng oligo-dT and 25 ng random hexamer primers. Real
Time-PCR assays were performed with the ABI7900HT
System using the QuantiTect SYBR Green PCR Kit
(Qiagen) and premade or self-designed primers (Additional
file 1: Tables S1–S2). TBP was used as a reference gene.
Statistical comparisons were made by Mann–Whitney
U test with SPSS 21.Immunocytochemistry
Cells grown to 70% confluence were fixed with 100% ice-
cold methanol for 5 min, permeabilized in 0.1% Saponin-
TBS solution and blocked in 1% bovine serum albumin in
0.2% Tween-TBS for 30 min each. Cells were then incu-
bated with the primary antibodies NOTCH1 (Epitomics,
EP1238Y), JAG1 (Santa Cruz Biotechnology, H114), DLL1
(Santa Cruz Biotechnology, H-265; Abcam, ab84620) and
NOTCH2 (Abcam, ab8926) and subsequently with goat-
anti-mouse Alexa Fluor488 antibody. Nuclei were stained
with 1 μg/ml DAPI (Dako, Hamburg, Germany).Western blotting
Subconfluently grown cells were lysed in RIPA buffer
with protease and phosphatase inhibitors. Western blot
analysis after SDS-page was performed using primary
antibodies against NOTCH1 (Epitomics, EP1238Y), JAG1
(Santa Cruz Biotechnology, H114), DLL1 (Santa Cruz
Biotechnology, H-265; Abcam, ab84620), NOTCH2
(Abcam, ab8926) and α-tubulin (B-1-5-2, Sigma) as a con-
trol. Secondary antibodies labelled with HRP and the ECL
advanced or ECL Select kits (GE Healthcare) were used
for detection.Immunhistochemistry
Immunohistochemistry was performed by standard
techniques with antigen retrieval by citrate buffer pH 9.
Antibodies used were NOTCH1 (Epitomics), JAG1
(Santa Cruz) and DLL1 (Santa Cruz). Detection was
achieved via a biotin-conjugated polyvalent antibody
with an avidin-biotin-peroxidase reagent (Scy Tek,
Logan, USA) and diamino-benzidine staining. Sections
were counter-stained with hemalum. The staining re-
sults of the reference tissues for antibody specificity are
provided in Additional file 1: Figure S1.
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The Notch receptor NOTCH1 and its ligand DLL1 are
significantly down-regulated in urothelial carcinoma tissues
Expression of several Notch pathway components was
measured at the mRNA level by qRT-PCR in a well-
characterized set of invasive urothelial carcinoma and
normal bladder tissue samples that we had previously
used for other studies [27]. Expression of NOTCH1 and
NOTCH2 was significantly decreased in almost all uro-
thelial cancers (Figure 1A-B). NOTCH3 expression was
generally unchanged in cancer tissues. NOTCH4, which
marks endothelial cells, was strongly expressed in bladderFigure 1 Expression of Notch pathway components in bladder tissues
benign and 30 tumour bladder tissue samples was measured by qPCR for
ligands (C) DLL1, (D) JAG1, (E) JAG2, nuclear factors (F) CBF1, (G) SKIP, (H) M
(K) HES5 and (L) HEY1. Data are represented as box plots. Statistical compa
made by the Mann–Whitney U Test using SPSS version 21.tissues but rarely detectable in cultured cells (data not
shown). Among the ligands, DELTA1 (DLL1) expression
was strongly and significantly decreased in cancer tissues,
whereas JAGGED1 (JAG1) and JAGGED2 (JAG2) mRNA
levels were not significantly changed (Figure 1C-E). Ex-
pression of DELTA3 and DELTA4 was undetectable in
normal and cancer tissues. None of the nuclear compo-
nents, KDM5A, MAML1, SKIP and CBF1 showed sig-
nificant expression changes between normal and cancer
tissues (Figure 1F-I). Expression of HES1 and HEY1 was
rather enhanced in cancer tissues, reaching significance
for HES1, whereas HES5 was unchanged (Figure 1J-L).. Relative mRNA expression of Notch pathway components in 11
the Notch receptors (A) NOTCH1, (B) NOTCH2, for the canonical
AML1, (I) KDM5A as well as the potential Notch target genes (J) HES1,
risons between benign and tumour bladder tissue expression were
Table 1 Overview of IHC staining results in 26 urothelial
cancers
Case # Stage Grade Metastasis NOTCH1 DLL1 JAG1
1 pTa Low - 1 3 2
2 pTa Low - 0 2 2
3 pTa Low - 1 2 2
4 pTa Low - 0 2 1
6 pTa Low - 1 1 1
7 pTa High - 1 2 2
9 pTa High - 1 2 1
12 pTa High - 1 2 2
19 pTa High - 0 1 2
20 pTa High - 0 1 1
25 pTa Low - 1 3 2
8 CIS High - 1 2 2
10 pT1 High - 1 2 2
11 pT1 High - 1 2 2
18 pT1 High - 0 1 1
23 pT1 High - 0 1 1
24 pT1 High - 0 1 1
13 pT2 High - 0 1 1
22 pT2 High - 0 1 1
29 pT2 High - 0 1 1
14 pT3 High + 0 1 1
15 pT3 High - 1 2 2
26 pT3 High + 0 0 0
27 pT4 High + 0 0 1
34 pT4 High + 0 1 1
35 pT4 High + 1 2 1
Intensity of staining was rated by two independent observers as 3 (strong
compared to normal bladder urothelium), 2 (comparable to normal), 1 (weak
or very weak compared to normal), 0 (undetectable).
Figure 2 Immunohistochemical detection of NOTCH1 and its ligands
benign urothelium (corresponding normal tissue from case #15) NOTCH1 a
umbrella cells and the membranes predominantly of intermediate cells. Sta
conversely detectable more strongly in the lower cell layers, mostly in the
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and JAG1 proteins is commonly changed in urothelial
carcinoma
Expression of NOTCH1, DLL1 and JAG1 was further
analysed by immunohistochemistry in a set of paraffin-
embedded tissues covering urothelial carcinomas of all
stages and grades (Table 1). In normal urothelium,
NOTCH1 was predominantly localized at the membranes
of intermediate cells and, more strongly, of umbrella cells.
Staining of basal cells was weak. No nuclear staining was
observed in UC compared to breast cancer (Additional
file 1: Figure S1A). The distribution of DLL1 was very
similar. JAG1 was observed in the cytoplasm and at the
membranes of lower urothelial layer cells (Figure 2). Ex-
pression and intracellular distribution of the three proteins
changed in urothelial carcinomas (Figure 3A). NOTCH1
and JAG1 decreased with increasing tumour stage and be-
came undetectable in several high stage tumours. In low
grade papillary tumours both proteins remained mainly
associated with the plasma membrane, whereas residual
protein in higher grade and stage cancers was essentially
cytoplasmic. DLL1 remained expressed in low grade papil-
lary tumours, albeit with a more cytoplasmic localization.
In higher grade and stage cancers, DLL1 was diminished,
often heterogeneously expressed and delocalized to the
cytoplasm and focally even to nuclei (Figure 3B). An over-
view of the staining results is provided in Table 1.
In UC cell lines NOTCH1 mRNA was likewise de-
creased compared to normal cultured urothelial cells
(UP), whereas NOTCH2 expression was only slightly di-
minished. Expression of DLL1 was strongly reduced, but
that of JAG1 and JAG2 less so (Figure 4). No significant
differences were observed for the nuclear components
CBF1 and SKIP whereas KDM5A and MAML1 were
strongly expressed in several UC cell lines. Expression of
the putative target genes HES1 and HEY1 was increased
in individual UC cell lines only.
As in tissues, the changes in the mRNA expression of
Notch pathway components in cell lines extended to theDLL1 and JAG1 in a benign bladder tissue. In this representative
nd DLL1 are localized in the cytoplasm and plasma membranes of
ining in the basal layer is weak, especially for NOTCH1. JAG1 is
cytoplasm and weakly at the plasma membrane.
Figure 3 Immunohistochemical staining of NOTCH1 and its ligands DLL1 and JAG1 in representative bladder tumour tissues.
(A) NOTCH1, DLL1 and JAG1 staining decreased with tumour invasiveness and became undetectable for NOTCH1 and JAG1 in several muscle invasive
bladder tumours. (B) Two examples for intratumoral heterogeneity of DLL1. [1] membrane staining, [2] nuclear staining, [3] no detectable staining.
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expressed robust amounts of the processed cytoplasmic
NOTCH1 fragment, which was depleted severely in all
UC cell lines. DLL1 was likewise more strongly expressed
in UP and in cell lines from papillary tumours. Contrasting
with the general downregulation of NOTCH1 and DLL1,
JAG1 protein remained comparable between UC and nor-
mal cells. NOTCH2 signals likely corresponding to full-
length NOTCH2 and N2CTD were rather increased in cell
lines with a mesenchymal phenotype (Figure 5). Immuno-
cytochemistry revealed membranous and cytoplasmic
localization of NOTCH1 and JAG1 in papillary UC lines
and weak cytoplasmic staining in invasive UC cells
(Additional file 1: Figure S2). As in tissues, DLL1 was often
heterogeneously distributed between cells with nuclear orcytoplasmic staining. NOTCH2 was predominantly local-
ized in nuclei in papillary urothelial cell lines, but predom-
inantly cytoplasmic in invasive urothelial cell lines.
Canonical Notch signalling is inactive, but remains
inducible by NOTCH1 in urothelial carcinoma cell lines
To measure canonical Notch signalling activity at its
final step in the nucleus, we applied a pair of reporter
gene plasmids with multiple binding sites for CBF1 func-
tional in pJH26A, but mutated in pJH28A. Their activity
ratio reflects the nuclear output of the pathway. As a
positive control, the mammary carcinoma cell line T47D
yielded a pJH26A/28A ratio of 11:1 indicating the ex-
pected high pathway activity (Figure 6A). UC cell lines
showed ratios between 1:2 and 1:5 (Figure 6B) indicating
Figure 4 Expression of Notch pathway components in urothelial cells. Relative mRNA expression in 8 normal urothelial cell cultures (x) and
16 urothelial cancer cell lines, subdivided in 7 papillary UC (♦) 9 invasive UC (■) as well as 3 non-UC bladder cancer cell lines (▲), was measured
by qPCR for the Notch receptors (A) NOTCH1, (B) NOTCH2, for the canonical ligands (C) DLL1, (D) JAG1, (E) JAG2, the nuclear factors (F) CBF1,
(G) SKIP, (H) MAML1, (I) KDM5A as well as the potential Notch target genes (J) HES1, (K) HES5 and (L) HEY1.
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ween individual cultures from weak repression (1:2) to
moderate activation (3:1). Co-transfection of a plasmid
expressing active N1ICD further increased Notch nu-
clear signalling in normal UPs (Figure 6C) and also in
the UC cell lines showing that the Notch signalling path-
way can in principle be activated by overexpression of
NOTCH1. However, Notch reporter activation increased
with higher amounts of plasmid in UPs, but not incarcinoma cells (Figure 6D), suggesting a toxic effect or
strong negative feedback factors in the latter. More
moderate activation was achieved by transfecting a plas-
mid expressing unprocessed NOTCH1 (N1-FL). Expres-
sion of both N1ICD and N1-FL after transfection was
verified by western blotting (Figure 6E-F).
To further investigate Notch signalling at the tran-
scriptional level, we additionally applied another pair of
reporters containing the natural HES1 promoter with
Figure 5 Expression of Notch pathway component proteins in urothelial cells. Western Blot analysis of Notch ligands and receptors in
urothelial cancer cell lines compared to a primary normal urothelial cell culture (UP). Top to bottom: Analysis with a JAG1 antibody resulted in
two signals at approximately [1] = 170 kD and [2] = 130 kD, likely corresponding to JAG1 full-length protein and its processed extracellular domain.
Signal [2], in particular, was strongly decreased in invasive UC cell lines compared to normal urothelial and papillary UC cells. DLL1 protein was
detectable at the expected size of 75 kD [3]. The signal was decreased in invasive UC cell lines compared to papillary UC and normal urothelial
cells. Analysis with NOTCH1 antibody resulted in an approximately 120 kD band [4] indicating a C-terminal NOTCH1 fragment which was strongly
diminished in urothelial cancer cell lines. Band [5] at ~300 kD likely corresponds to full-length NOTCH2 protein and band [6] at ~120 kD to the
processed C-terminal NOTCH2 fragment. No general decrease in expression is discernible in the UC cell lines. α-Tubulin (Sigma) was used as a
quality and loading control.
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Figure 6G, both HES1 reporters yielded comparable lu-
ciferase activity under basal conditions in four different
UC cell lines, indicating inactive nuclear Notch signal-
ling. Co-transfection of the active N1ICD domain acti-
vated the wildtype promoter in all four cell lines.
To obtain an indication whether lack of ligand ex-
pression contributed to Notch pathway inactivity, we in-
vestigated the effect of extraneous DLL1 ligand, as this
ligand was most prominently reduced at mRNA and
protein levels in UC tissues and cell lines. For that pur-
pose, we employed an experimental setup, in which the
extracellular domain of the DLL1 ligand is immobilized
as a Fc-fusion protein to cell culture plates through
anti-Fc-antibodies [26]. Two urothelial cancer cell lines,
BFTC905 and VM-Cub1, transfected with full-length
NOTCH1 or vector were seeded on the coated plates
and Notch pathway activity was determined via co-
transfected Notch reporter plasmids pJH26A and
pHJ28A. As in the previous experiments, Notch signal-
ling was induced by transfection of full-length NOTCH1,
but neither further enhancement nor increased basal
activity were achieved by exposure to the immobilized
extracellular DLL1 domain (Figure 6H). This finding
suggests that NOTCH1 is the most limiting factor for
canonical Notch activity in UC cell lines.Inhibition of Notch signalling by GSIs does not affect UC
proliferation
If canonical Notch signalling is indeed inactive in UC, in-
hibition of the essential γ-secretase cleavage should not
affect cell proliferation. Therefore, we analysed the effects
on cell proliferation and cell survival after pharma-
cological γ-secretase inhibition in urothelial cells. Three
inhibitors, i.e. DAPT, L-685,458 and Compound E, inhibit
the protease presenilin forming part of γ-secretase in
general, whereas Compound W specifically blocks the
processing of one substrate (APP), providing a specificity
control. Indeed, in HEK293 cells which are sensitive to
inhibition of Notch signalling, the former three inhibitors,
but not Compound W, inhibited proliferation in a dose-
dependent manner (Figure 7). In contrast, the specific
γ-secretase inhibitors did not inhibit proliferation of the
UC cell lines better than Compound W. Rather, DAPT
and L-685,458 tended to increase vital cell numbers.
Notch overexpression results in nuclear abnormalities and
diminishes clonogenicity
Whereas pharmacological Notch signalling inhibition did
not diminish proliferation in urothelial cancer cell lines,
overexpression of N1-FL or N1ICD diminished clonogeni-
city of urothelial carcinoma cell lines (Figure 8A). In short
term transfections, neither protein induced substantial
Figure 6 Notch signalling pathway activity in urothelial cells. Notch activity was determined by the ratio of the Notch-dependent wildtype
plasmid pJH26A to the Notch-independent mutant plasmid pJH28A. p850-luc and pGL3 plasmids were used as controls. (A) The mammary
carcinoma cell line T47D showed a ratio 11:1 suggesting Notch activity. (B) Results of reporter gene assays in primary urothelial cell cultures (UP)
and urothelial cancer cell lines in comparison to T47D. (C-D) Induction of Notch activity after transfection of pIRES2-N1ICD in (C) two normal
urothelial cell cultures (UP234 and UP188) or (D) UC cell lines BFTC905, VM-Cub1 and 5637. In contrast to the UP cultures, in UC lines Notch
activity decreased upon further increasing plasmid concentration (light grey BFTC905, dark grey VM-Cub1, black 5637). (E) Successful overexpression of
N1ICD and NOTCH1 full-length (N1-FL) plasmids after 24 hours in UC lines proven by Western Blot with a Notch antibody detecting the C-terminal
fragment (Epitomics) with α-Tubulin as a loading control (F) inducing Notch activity in reporter assays. pJH26A to pJH28A ratios are normalized to the
empty vector pIRES2. (G) Reporter gene assay with a HES1 promoter with intact or without CBF1 binding sites driving luciferase expression in the four
UC lines. Basal luciferase activities were not significantly different between the reporters, whereas co-transfection of the N1ICD fragment significantly
activated the HES1 promoter. (H) Assay for DLL1-dependent activation of the Notch signalling pathway in VM-Cub1 and BFTC905 cells. Notch pathway
activity was measured by reporter plasmids cotransfected with or without full-length NOTCH1 (N1-FL) and exposed to immobilized extracellular DLL1
domain or IgG. Changes in the pJH26A/pJH28A reporter ratio were not significant between IgG vs. DLL1 exposure (independent of N1-FL), whereas
induction by N1-FL was highly significant (T-tests p < 0.01) in each case.
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transfected cells in four cell lines declined only weakly
over three days by at most 45% (data not shown). How-
ever, between 35% and 64% of N1ICD-transfected cells
displayed various striking nuclear abnormalities compared
to controls, especially a tendency towards multinuclearity
and instances of mitotic catastrophes and nuclear frag-
mentation (Figure 8B).
Discussion
Taken together, our results from tissues and cell lines
suggest that canonical Notch signalling towards the nu-
cleus is inactive in urothelial carcinoma, especially in the
invasive subtype. NOTCH1 and DLL1 were most con-
sistently diminished in both cell lines and tissues. Down-
regulation of these factors is in accord with a previous
report [19], whereas another paper reported decreased
NOTCH1 expression in high-grade invasive UC tissues
only, with more pervasive cytoplasmic localization [28].
The mechanisms underlying these changes remain to be
determined. Sequencing data from the TCGA con-
sortium (http://cancergenome.nih.gov/) indicate only few
mutations in Notch pathway components in urothelial
carcinoma (Additional file 1: Table S3). The frequency of
NOTCH1 mutations is about 5% and is thus considerably
lower than in head-and-neck squamous cell carcinomas
[16]. A more likely cause of downregulation are copyFigure 7 Effects of treatment with γ-secretase inhibitors (GSI) on UC p
treated with the indicated concentrations of DAPT, L-685,458, Compound E
viability was analysed by a MTT-Assay.number changes at chromosome 9q34 (where NOTCH1 is
encoded) which occur in up to 30% of invasive UC. How-
ever, neither mutations nor gene loss can fully account for
the high prevalence of NOTCH1 downregulation. As both,
NOTCH1 and DLL1, are predominantly localized in more
differentiated cells in the normal urothelium, their de-
creased expression in tumours may conceivably reflect to
some extent the loss of this differentiated cell population.
In addition to downregulation, we frequently observed
delocalization of NOTCH1 and DLL1 to the cytoplasm
in tumour cells. Delocalization of NOTCH proteins to
the cytoplasm in some cells reflects lack of activation by
external ligands in trans but enables cis-inhibition by li-
gands expressed in the same cell compartment [29,30].
Candidates for that function are JAG1 and especially
JAG2, which appear to be retained or in the case of
JAG2 even upregulated in invasive UC [31]. JAG1 was
mostly cytoplasmic in tumour cells and is thus unlikely
to contribute to trans-signalling. Notably, the distribu-
tion of JAG1 in normal urothelium is quite similar to
that of p63 [32], a factor known to maintain basal cells
in many epithelia and to induce JAG1 in many instances.
The co-localization of DLL1 and NOTCH1 proteins in
normal urothelium suggests that DLL1 could be the
physiological ligand for NOTCH1 in this tissue. How-
ever, exposure of UC cell lines to immobilized DLL1,
which is considered to yield superior activation comparedroliferation. The indicated UC cell lines and HEK293 cells were
and the modulator Compound W for 48 hours after which cell
Figure 8 Effects of NOTCH1 re-expression on UC cell lines. (A) Five independent colony forming assays with triplicate plates for each experiment
after transfection of plasmid constructs expressing NOTCH1 intracellular domain (N1ICD) or full-length protein (N1-FL) compared to control constructs.
Clone numbers were counted after selection for three weeks with either G418 (pIRES-N1ICD/pIRES-2) or Zeozin (pcDNA4to-N1-FL/pcDNAto-lacZ). The
student’s T Test was carried out for statistical analysis. Colony forming potential was significantly decreased in N1ICD and N1-FL transfected cells.
(B) Nuclear abnormalities typically appearing after transfection of N1ICD into UC cell lines. Note nuclear enlargements, deformation, micronuclei,
fragmentation, multinuclearity and mitotic catastrophe in cells expressing N1ICD (green) as compared to others. DNA was counterstained with DAPI
(blue). Further analysis is shown in Additional file 1: Table S4.
Greife et al. BMC Cancer 2014, 14:628 Page 11 of 13
http://www.biomedcentral.com/1471-2407/14/628to soluble ligand [26] did not enhance activation of a
Notch-dependent reporter by transfected NOTCH1
protein, least activate canonical signalling by itself.
We note that NOTCH2 expression was less strongly
changed than that of NOTCH1 and that active N2ICD
could be detected in the nuclei of some UC cell lines.
Interestingly, it appeared more strongly expressed in mes-
enchymal UC cell lines albeit localized to the cytoplasm.
Increased expression of NOTCH2 in UC cell lines with a
mesenchymal phenotype as compared to lines with an epi-
thelial phenotype has recently been reported by others
[33,34]. The same authors observed that NOTCH2, but
not NOTCH1, favors epithelial-mesenchymal transition
and cell migration in UC cell lines [33,34]. Collectively,these findings suggest divergent functions of NOTCH1
and NOTCH2 in UC, which have also been observed in
other cancers [35,36]. Nevertheless, despite the expression
of N2CTD at a level comparable to that in normal uro-
thelial cells, two different NOTCH-dependent reporters
showed no evidence for canonical pathway activity in the
UC cell lines. Likewise, γ-secretase inhibitors did not
block cell proliferation in UC cell lines. These findings
argue that canonical Notch signalling to the nucleus is
inactivated in urothelial carcinoma. As a consequence,
it seems plausible that the effects of NOTCH2 in
mesenchymal UC cell lines, considering especially its
cytoplasmic localisation, could be exerted by non-canonical
signalling.
Greife et al. BMC Cancer 2014, 14:628 Page 12 of 13
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was significantly increased compared to normal bladder,
despite the significant downregulation of NOTCH1,
NOTCH2 and DLL1. Although no upregulation of HES1
was observed in the UC cell lines compared to normal
urothelial cells, this finding is somewhat puzzling, since
HES1 is a common target gene of the canonical Notch
pathway. However, target genes of the pathway vary
strongly between tissues and even HES1 is not a univer-
sal target [18]. Moreover, HES1 is regulated by several
pathways, including Hedgehog [37], ATF2 [38], and sig-
nalling through JNK1 [39]. In UC cell lines, a reporter
plasmid driven by the HES1 promoter was similarly ac-
tive, if the CBF sites were wild-type or mutant, sup-
porting our conclusion that canonical Notch signalling is
inactive. However, luciferase was induced by N1ICD
cotransfection indicating that HES1 can be a target of an
active Notch pathway in urothelial cells. Collectively,
these findings suggest that the increased expression of
HES1 in UC tissues could reflect its predominant regula-
tion by a different pathway in the absence of canonical
Notch signalling.
In normal urothelial cells and urothelial carcinoma cell
lines, overexpression of full-length NOTCH1 or its ac-
tive intracellular domain induced canonical reporters
but was not compatible with long-term proliferation of
UC cells. Inhibition of proliferation did not appear to
occur by straightforward inhibition of cell cycling or by
a major induction of apoptosis. Rather, NOTCH1 trans-
fected cells often showed misshaped or abnormally large
nuclei or became obviously binuclear. Intriguingly, in
normal urothelium NOTCH1 is localized in the upper
layers together with its likely ligand DLL1, where they
might contribute to terminal differentiation. In parti-
cular, umbrella cells of the urothelium are usually poly-
ploid [40]. In squamous epithelia, Notch signalling is
most important for establishing the commitment to
terminal differentiation in the suprabasal layer [41,42].
Notch signalling is well-established as a regulator of
polyploidization in Drosophila, but may also act in this
fashion in certain mammalian cells [43]. Evidently, the
urothelium is one tissue, where this function should be
investigated in detail. The observed effects of NOTCH1
overexpression on UC cells may thus be conceptualized
by assuming that it induces a failed attempt at diffe-
rentiation. Evidently, the effects of pharmacological in-
hibition of the Notch pathway and genetic inactivation
of individual components such as NOTCH1, DLL1 and
NOTCH2 should be studied in culture and animal
models of urothelial differentiation.
Conclusions
Collectively, our findings indicate that canonical Notch
signalling is lost in urothelial carcinoma mainly viainactivation of NOTCH1, which in normal urothelium
may promote specific steps of urothelial differentiation.
As it has been shown that inhibition of the γ-secretase
leads to hyperproliferation in tissues, where Notch sig-
nalling promotes differentiation [9], inhibition of Notch
does therefore not appear to represent a useful thera-
peutic approach to UC. Instead, urothelial differentiation
might become disturbed as an adverse effect of long-
term treatment of other tumour entities with drugs tar-
geting canonical NOTCH signalling.
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